As we incorporate targeted therapies and immune checkpoint inhibitors into the standard treatment of patients with advanced lung cancer, patient outcomes are improving in terms of both quantity and quality. The KEYNOTE-189 study demonstrated that the addition of pembrolizumab to pemetrexed–platinum chemotherapy in patients with advanced non-squamous non-small-cell lung cancer without EGFR or ALK aberrations significantly improved overall survival (hazard ratio [HR] 0·49 [95% CI 0·38–0·64]; p<0·001), irrespective of PD-L1 tumour proportion score, compared with chemotherapy alone. In The Lancet Oncology, Marina Garassino and colleagues present the health-related quality-of-life (HRQOL) results from this practice-changing trial.

中文翻译：

---

推进肺癌的全身治疗：质量还是数量？

随着我们将靶向疗法和免疫检查点抑制剂纳入晚期肺癌患者的标准治疗方法，患者的治疗效果在数量和质量上都在提高。KEYNOTE-189研究表明，在没有EGFR或ALK异常的晚期非鳞状非小细胞肺癌患者中，在培美曲塞-铂化疗中加用派姆单抗显着改善总体生存率（危险比[HR] 0·49 [95] [％CI 0·38-0·64]； p <0·001），与PD-L1肿瘤比例评分无关，与单纯化疗相比。Marina Garassino及其同事在《柳叶刀肿瘤》杂志上介绍了这项改变习惯的试验所产生的健康相关生活质量（HRQOL）结果。